AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit
There is a quiet tension in the market for anyone who held Aquestive Therapeutics stock lately. The Rosen Law Firm is officially calling for investors who bought AQST between June 16, 2025, and January 8, 2026, to step forward. They’re looking for a lead plaintiff for a securities fraud lawsuit, and the hard deadline is May 4, 2026.
I’m sitting here listening to the hum of the office AC—it’s been running all day—and thinking about how these deadlines always seem to sneak up. If you bought those shares during the “Class Period,” you might be entitled to some compensation, and the firm says it’s done on a contingency basis, so you aren’t paying legal fees out of your own pocket. At least not directly.
So what actually happened? The lawsuit claims the company wasn’t entirely transparent about its New Drug Application for Anaphylm. Specifically, they allegedly downplayed the “human factors”—think the actual, physical reality of packaging, labeling, and how a patient is supposed to use that sublingual film in a real-world emergency. It’s the kind of technical detail that investors usually gloss over until the market forces them to pay attention.
Anyway, if you want to join, Misryoum has noted that you can hit up their portal or call Phillip Kim. You don’t have to do anything yet, honestly. You could just remain an absent class member, though if you want to actually steer the litigation as a lead plaintiff, you have to move the court by that May 4 date. Or maybe you just wait and see if a class even gets certified—which, spoiler, it hasn’t been yet.
Rosen Law is positioning itself as the right choice here, citing their history with large settlements and their “Titan of the Bar” pedigree. They’re pretty aggressive about warning investors against “middlemen” firms that might just pass your case off to someone else. It’s a reminder to be careful who you hire, or maybe just be careful who you trust with your portfolio? It’s a lot to navigate when you’re just trying to get a return on your investment.
Ultimately, the choice is yours. You can pick your own counsel or just sit tight. The firm has a track record, sure, but whether that translates to this specific case against Aquestive remains to be seen. You can find their contact info on the Misryoum wire, or just keep an eye on their socials if you don’t want to commit to anything today. I’m not sure if I’d want the headache of being a lead plaintiff myself, but then again, that’s up to you.